Follicum AB today announces that the European Patent Office (EPO) has approved the patent EP 3 618 845 B1, which refers to the company’s novel peptides that are being developed to treat diabetes. The approval follows the previous provisional approval by the EPO announced on March 20, 2020. The approval by the EPO of patent […]
Presentation BioStock Life Science Summit 2020, November 18
Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.
Read moreFollicum AB today announces that the European Patent Office (EPO) has approved the patent EP 3 618 8...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,...
Follicum AB announced today that the patent which previously (June 22, 2020) received a so-called No...
BioStock published an article on 17 December 2020 about Follicum, which can be read in full below. A...
On 25 November 2020, Aktiespararna published their analysis of Follicum on their website. The analys...
BioStock published an article on 2 November 2020 about Follicum, which can be read in full below. La...
Follicum will attend the BIO International Convention Digital Event on 10-11 & 14-18 June 2021....
Follicum will attend the World Congress for Hair Research in Melbourne (WCHR), Australia, on 22-25 A...
